MedPharm CSO to present at FDA’s Generic Drug Science and Research Initiatives Public Workshop

Guildford, UK and Durham, NC, May 2024 – MedPharm’s Chief Scientific Officer, Dr. Jon Lenn, will present on the chemical stability of benzoyl peroxide and the potential formation of benzene in topical products at the FDA’s public workshop on Generic Drug User Fee Amendments (GDUFA) on May 21st, 2024.  

The GDUFA Public Workshop, an annual event, serves as a platform to share the latest updates on science and research initiatives for generic drugs. It also offers an opportunity for the public to contribute their insights and perspectives on these initiatives. This event is free and accessible to all, either in-person or virtually.

CEO Lynn Allen expressed MedPharm’s enthusiasm for this event, “We are excited to present on important topics that affect the generic space. It’s an honor to present ideas to the FDA. The topics covered throughout the workshop, particularly during Jon’s presentation, are not only timely but also critical to our industry. We look forward to sharing our insights and learning from others in this collaborative setting.”  

According to the FDA’s website, the workshop will focus on research needed to address scientific knowledge gaps and challenges impacting the development and regulatory assessment of generic products. This includes topics related to drug-device combination products and predictive tools to improve the efficiency of generic product development.  

FY 2024 Generic Drug Public Workshop including MedPharm

About MedPharm

MedPharm is a global contract provider of topical and transdermal formulation development services specializing in reducing risk through unique, cost-effective, and industry-leading performance testing models. MedPharm offers innovative dermal/transdermal, respiratory, mucosal membrane and ophthalmic product development solutions with locations in the United Kingdom and the United States. For more information, visit or follow us on LinkedIn.